Vaccine value profile for leishmaniasis
2023/10/06 by Paul M. Kaye, Greg Matlashewski, Sakshi Mohan +5 · 16 citations
Medicine · #Research on Leishmaniasis Studies
paper · doi:10.1016/j.vaccine.2023.01.057
Abstract
Leishmania infections are global, occurring in 98 countries and all World Health Organization (WHO) regions with 600 million to 1 billion people at risk of infection. Visceral leishmaniasis is associated with almost 20,000 reported deaths annually, with children under 5 years of age being at the greatest risk of mortality. Amongst WHO-recognised Neglected Tropical Diseases (NTDs), leishmaniasis is one of the most important in terms of mortality and morbidity. With an increasing global burden of disease and a growing threat from climate change, urbanisation and drug resistance, there remains an imperative to develop leishmaniasis vaccines. New tools to understand correlates of protection and to assess vaccine efficacy are being developed to ease the transition into larger scale efficacy trials or provide alternate routes to licensure. Early indications suggest a diverse portfolio of manufacturers exists in endemic countries with an appetite to develop leishmaniasis vaccines. This Vaccine Value Profile (VVP) provides a high-level, comprehensive assessment of the currently available data to inform the potential public health, economic, and societal value of leishmaniasis vaccines. The leishmaniasis VVP was developed by a working group of subject matter experts from academia, public health groups, policy organizations, and non-profit organizations. All contributors have extensive expertise on various elements of the leishmaniasis VVP and have collectively described the state of knowledge and identified the current gaps. The VVP was developed using only existing and publicly available information.
Citations
Cited by
- Breaking the deadlock in antigen discovery for Leishmania vaccines
- Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis. [europepmc]
- The Full Value of Vaccine Assessments Concept-Current Opportunities and Recommendations. [europepmc]
- Nicotinamide mitigates visceral leishmaniasis by regulating inflammatory response and enhancing lipid metabolism. [europepmc]
- From classical approaches to new developments in genetic engineering of live attenuated vaccine against cutaneous leishmaniasis: potential and immunization. [europepmc]
- Investigating disease awareness of cutaneous leishmaniasis in rural Sri Lanka to inform public health services: a cross-sectional study. [europepmc]
- At the genetic crossroads of Leishmania: Emerging hybrids reshaping disease patterns. [europepmc]
- LeishTec vaccination disrupts vertical transmission of Leishmania infantum. [europepmc]
- Leishmania donovani's protein tyrosine phosphatases interact with DUF21 and respond to environmental magnesium. [europepmc]
- Genome-Wide Identification of Novel miRNAs and Infection-Related Proteins in Leishmania major via Comparative Analysis of the Protozoa, Vectors, and Mammalian Hosts. [europepmc]
- Understanding the complexity of cutaneous leishmaniasis patient journey in endemic rural Sri Lanka: a qualitative study. [europepmc]
- Intracellular Parasitic Infections Caused by Plasmodium falciparum , Leishmania spp., Toxoplasma gondii , Echinococcus multilocularis , Among Key Pathogens: Global Burden, Transmission Dynamics, and Vaccine Advances-A Narrative Review with Contextual Insights from Armenia. [europepmc]
- Global Landscape of Molecular and Immunological Diagnostic Tests for Human Leishmaniasis: A Systematic Review and Meta-Analysis. [europepmc]
- mRNA based vaccines and therapeutics for parasitic infections: a comprehensive review. [europepmc]
- Leishmaniasis vaccine research: current status and new directions. [europepmc]
- Accelerating vaccine research and development for skin neglected tropical diseases: A case for leishmaniasis, leprosy, and Buruli ulcer. [europepmc]
Related